Related Experiment Video
Updated: Jun 16, 2025
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Exposure to Mycophenolic Acid and Its Clinical Response in an Indian Pediatric Population with Nephrotic Syndrome
R V Deepthi1, Manjusha Arumadi1, Vishnu Eriyat2
1Department of Pediatric Nephrology, Christian Medical College, Vellore, Tamil Nadu, India.
Background:
Children with nephrotic syndrome experience many side effects and frequent relapses when treated with steroids and other drugs. Mycophenolic acid (MPA) is one of the effective and least toxic drug for the treatment of nephrotic syndrome. This drug needs to be monitored for maximal efficacy and minimal toxicity. The therapeutic reference range for this drug is not established for the aforementioned patient population of Indian origin.
Materials And Methods:
In this observational study, children with nephrotic syndrome on mycophenolate mofetil were followed up for a minimum duration of three months. Following this, their clinical status (relapse/remission) was determined and the mycophenolate exposure was measured for over 12 hours.
Results:
A total of 34 participants were included, with 17 (50%) in relapse. Median MPA Area under the curve over 12 hours (AUC0-12h) (36.5 µg·h/ml) in the remission group differed significantly compared to that in the relapse group (17.2 µg·h/ml).
Conclusion:
Higher exposure to MPA AUC0-12h is associated with clinical remission of pediatric nephrotic syndrome.
Insights
Mycophenolic acid (MPA) monitoring is crucial for children with nephrotic syndrome. Higher MPA exposure (AUC0-12h) is linked to better remission rates in pediatric nephrotic syndrome patients.
Area of Science:
- Pediatric Nephrology
- Pharmacokinetics
- Clinical Pharmacology
Background:
- Steroid treatment for nephrotic syndrome causes side effects and relapses.
- Mycophenolic acid (MPA) offers an effective, less toxic alternative for nephrotic syndrome.
- Therapeutic reference ranges for MPA are not established in Indian pediatric nephrotic syndrome patients.
Purpose of the Study:
- To investigate the relationship between mycophenolate mofetil (MPA) exposure and clinical outcomes in pediatric nephrotic syndrome.
- To establish potential therapeutic targets for MPA in this patient population.
Main Methods:
- Observational study of children with nephrotic syndrome treated with mycophenolate mofetil.
- Minimum follow-up duration of three months.
- Measurement of mycophenolate exposure (AUC0-12h) and determination of clinical status (relapse/remission).
Main Results:
- 34 children were included; 17 (50%) experienced relapse.
- Median MPA AUC0-12h was significantly higher in the remission group (36.5 µg·h/ml) compared to the relapse group (17.2 µg·h/ml).
Conclusions:
- Higher MPA exposure (AUC0-12h) is associated with clinical remission in pediatric nephrotic syndrome.
- MPA monitoring is essential for optimizing treatment efficacy and minimizing toxicity in children with nephrotic syndrome.
